GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

OCUL · Dec 31, 2024

OCULAR THERAPEUTIX, INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001558370-25-002000General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

2.02% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-211.35% · OPTIONAL · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

4.77% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

91.17% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-269.57% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

200.30% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

51.96% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History9 statesHistory building

Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20240/7 normalizedLevel 3 Mar 31, 20250/7 normalizedLevel 3 Jun 30, 20250/8 normalizedLevel 3 Sep 30, 20250/8 normalizedLevel 3 Dec 31, 20250/8 normalizedLevel 3 Mar 31, 20260/8 normalizedLevel 3 Jun 30, 20267/8 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Increased

Previous: 0.58%
Current: 2.02%
Delta: 1.44%

Cash Generation Increased

Previous: -237.01%
Current: -211.35%
Delta: 25.66%

Inventory Pressure Decreased

Previous: 15.59%
Current: 4.77%
Delta: -10.82%

Margin Increased

Previous: 89.88%
Current: 91.17%
Delta: 1.29%

Profitability Increased

Previous: -298.20%
Current: -269.57%
Delta: 28.63%

R And D Intensity Decreased

Previous: 240.22%
Current: 200.30%
Delta: -39.92%

Sbc Intensity Increased

Previous: 43.05%
Current: 51.96%
Delta: 8.90%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · OCUL Fundamental State →Has State · OCULAR THERAPEUTIX, INC →Transitioned To · OCUL Fundamental State →Transitioned To · OCUL CAPEX_INTENSITY_INCREASED →Transitioned To · OCUL CASH_GENERATION_INCREASED →Transitioned To · OCUL INVENTORY_PRESSURE_DECREASED →Transitioned To · OCUL MARGIN_INCREASED →Transitioned To · OCUL PROFITABILITY_INCREASED →Transitioned To · OCUL R_AND_D_INTENSITY_DECREASED →Transitioned To · OCUL SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.